Abstract
To analyze the interaction between the neurokinin-1 (NK-1) receptor and G-protein coupled receptor kinases (GRKs), we performed bioluminescence resonance energy transfer2 (BRET2) measurements between the family A NK-1 receptor and GRK2 and GRK5 as well as their respective kinase-inactive mutants. We observed agonist induced interaction of both GRK5 and GRK2 with the activated NK-1 receptor. In saturation experiments, we observed GRK5 to interact with the activated receptor in a monophasic manner while GRK2 interacted in a biphasic manner with the low affinity phase corresponding to receptor affinity for GRK5. Agonist induced GRK5 interaction with the receptor was dependent on intact kinase-activity, whereas the high affinity phase of GRK2 interaction was independent of kinase activity. We were surprised to find that the BRET2 saturation experiments indicated that before receptor activation, the full-length NK-1 receptor, but not a functional C-terminal tail-truncated receptor, is preassociated with GRK5 in a relatively low-affinity state. We demonstrate that GRK5 can compete for agonist induced GRK2 interaction with the NK-1 receptor, whereas GRK2 does not compete for receptor interaction with GRK5. We suggest that GRK5 is preassociated with the NK-1 receptor and that GRK5, rather than GRK2, is a key player in competitive regulation of GRK subtype specific interaction with the NK-1 receptor.
Footnotes
-
J.L.H. was supported by The Danish Medical Research Council and the Danish National Research Foundation and N.D.H. was supported by the Royal Society (UK).
-
ABBREVIATIONS: 7TM, seven transmembrane; NK-1, neurokinin-1; GRK, G-protein-coupled receptor kinase; βarr, βarrestin; BRET, bioluminescence resonance energy transfer; RLuc, Renilla reniformis luciferase; SP, substance P; HEK, human embryonic kidney; BSA, bovine serum albumin; PBS, phosphate-buffered saline; wt, wild type.
-
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received June 7, 2007.
- Accepted November 6, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|